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Abstract
Background Various self-reported or clinician-reported (as a proxy) measures exist to quantify the burden of schizophrenia 
on patients. Evidence of the psychometric relationship between these measures to inform their practical use is limited.
Objectives Our objective was to conduct an exploratory analysis of the construct validity of patient-reported (EQ-5D, SF-6D, 
WEMWBS, SQLS subscales of Psychosocial, Motivation, Symptoms) versus clinician-reported measures (PANSS, CGI-SCH, 
NSA-4, HoNOS-PbR) to inform future use of patient-reported measures for burden-of-illness assessment and/or economic evaluation.
Methods In an adult patient population with schizophrenia, construct validity was assessed in relation to convergent 
and known-group validity. Convergent validity was assessed using Spearman’s rank absolute correlation strength (ACS: 
weak ≤ 0.3, moderate = 0.3 < 0.5, strong ≥ 0.5) and graphically using locally weighted scatterplot smoothing (LOWESS) 
techniques. Known-group validity was assessed using Cohen’s d absolute effect size (AES: small ≤ 0.5, moderate = 0.5 < 0.8, 
large ≥ 0.8). Floor and ceiling effects were assessed as a proxy of sensitivity in this cross-sectional study. Statistical signifi-
cance was assessed at the 5% threshold level (p < 0.05). Across head-to-head assessments, the frequency of producing the 
strongest ACS, largest AES, and statistically significant results determined the best overall construct validity.
Results Overall, 304 patients consented to the study. In relation to statistically significant results, the SF-6D most frequently 
exhibited the strongest ACS and largest AES against the clinician-reported measure scores (ACS range 0.084–0.436; AES 
range 0.043–0.746), and the SQLS Motivation subscale most frequently exhibited the weakest/smallest values (ACS range 
0.009–0.157; AES range 0.002–0.397), although these results were mixed according to the clinician-reported measure used 
for comparative analysis (ACS range 0.009–0.529; AES range 0.002–0.934).
Conclusion The SF-6D indicated the best (mostly moderate) construct validity but still missed the negative symptoms of the con-
dition. Although further evidence is required to confirm or refute these exploratory results, compared with the EQ-5D, the SF-6D 
can be self-reported to better capture generic health-related quality-of-life aspects of schizophrenia for the purpose of economic 
evaluation. The lack of construct validity for SQLS Motivation and Symptoms subscales were hypothesized post-hoc to be repre-
sentative of the complementary information elicited by the subscales not captured by the clinician-reported measures. Therefore, 
the SQLS can be self-reported to capture complementary (i.e., additional) information relative to clinician-reported measures.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4027 1-019-00358 -x) contains 
supplementary material, which is available to authorized users.
 * Matthew Franklin 
 matt.franklin@sheffield.ac.uk
Extended author information available on the last page of the article
Key Points for Decision Makers 
Compared with the EQ-5D, the SF-6D can be self-reported 
to better capture health-related quality-of-life aspects of 
schizophrenia for the purpose of economic evaluation.
The SQLS can be self-reported to capture complemen-
tary information relative to clinician-reported measures.
A more mental health-focused preference-based measure 
that can capture the negative symptoms of schizophrenia 
and that can be used for the purpose of economic analysis 
is still desirable for healthcare-related decision making.
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1  Background
Schizophrenia is a mental health disorder characterized by a 
range of different psychological impacts, including changes 
in thinking and behavior. The health-related quality of life 
(HRQoL) and social burden of schizophrenia is large, affect-
ing both patients and their caregivers, for example, their 
social and financial situation [1, 2]. Many outcome measures 
have been designed to assess the burden of schizophrenia. 
These measures may have different conceptual perspectives 
that can be condition specific, such as the Schizophrenia 
Quality-of-Life Scale (SQLS) [3], designed to capture schiz-
ophrenia-specific QoL aspects, or generic, such as the War-
wick-Edinburgh Mental Wellbeing Scale (WEMWBS) [4, 5], 
designed to capture broader outcomes and be applicable to 
more than one mental health condition. The WEMWBS has 
been assessed in individuals with schizophrenia but only as 
part of a mixed-diagnosis group [6], so it is unclear whether 
it is an appropriate measure for this population. Measures 
may also be categorised according to whether or not they 
are preference based; examples of preference-based measures 
include the three-level EuroQoL Five-Dimension (EQ-5D) 
[7, 8] and the Short-Form Six-Dimension (SF-6D) [9]. These 
preference-based measures are used to form a profile score 
that is converted into a preference-based index score (usu-
ally based on societal preferences) and thus allow economic 
evaluation of interventions using cost-utility analysis (CUA) 
to inform the allocation of resources by healthcare-governing 
agencies such as the UK National Institute for Health and 
Care Excellence (NICE) [10]. In CUA, QoL measured on a 
preference-based scale anchored at 0 (dead) to 1 (full health) 
is combined with length of life to generate quality-adjusted 
life-years (QALYs), allowing comparisons between inter-
ventions that affect quantity of life and/or QoL. However, 
while there can be “some confidence” in the use of generic 
measures (e.g., the SF-6D and EQ-5D) in patients with mood 
and anxiety disorders because of their demonstrated psycho-
metric validity and responsiveness [11], this is not the case 
with schizophrenia. In patients with schizophrenia, the data 
are less conclusive [11–13], and it has been argued that pref-
erence-based measures focused on the impact of the mental 
disorder (rather than generic measures covering both physical 
and mental health) should instead be considered [11].
The SQLS, WEMWBS, EQ-5D, and SF-6D are all self-
reported measures. Evidence suggests that, in people with 
schizophrenia, self-report should be interpreted with cau-
tion as condition-related aspects such as cognitive impair-
ment may impair reliability [14]. Measures completed by 
observers (e.g., clinicians), such as the Positive and Negative 
Symptom Scale (PANSS) [15] and Clinical Global Impres-
sion-Schizophrenia Change (CGI-SCH) [16] have been 
developed to aid assessment of the burden of schizophrenia.
Each measure differs in its features and constructs, and at 
times there is value in using more than one measure when 
the choice of measure(s) is based on the purpose of assess-
ment [17, 18]. When using more than one measure, the rela-
tionship between the measures should be considered, for 
instance, including a clinician-reported measure alongside 
patient-reported measures [19].
The overall aim of this analysis was to perform an explor-
atory assessment of the construct validity of patient-reported 
measures in the context of patients with schizophrenia to 
assess their potential utility when reflecting the burden of 
schizophrenia alongside clinician-reported measures.
2  Methods
2.1  Data
Data were drawn from a multicenter, non-interventional, 
cross-sectional survey designed to assess the burden of ill-
ness of people with persistent symptoms of schizophrenia 
[20] (ClinicalTrials.gov identifier: NCT01634542). The 
dataset included adult patients in the UK who had persis-
tent schizophrenia symptoms despite receiving adequately 
dosed antipsychotic treatment and who had not had an acute 
exacerbation in the last 3 months. Respondents and clini-
cians completed questionnaires at their usual clinic visits.
2.2  Outcome Measures
2.2.1  Patient‑Reported Measures
Patients completed the SQLS, a 30-item self-reported meas-
ure of schizophrenia-related QoL on a five-point item scale 
from 0 (best state) to 4 (worst state), with three subscales: 
(1) Psychosocial (15 items), (2) Motivation (and energy; 
seven items); and (3) Symptoms (and side effects; eight 
items). Each subscale has a range from 0 (best possible state) 
to 100 (worst possible health state), whereby the scoring and 
rescaling for each subscale follows the methods described 
by Wilkinson et al. [3]: the scale score (SS) equals the total 
of raw scores of each item in the scale  (RStot) divided by the 
maximum possible score of all the items in the scale  (RSmax), 
all multiplied by 100; i.e., SS = (RStot/RSmax) × 100. They 
also completed the WEMWBS, a 14-item scale of positive 
well-being and psychological functioning [21] with scores 
ranging from 14 (worst state) to 70 (best state). Two generic 
HRQoL preference-based measures were included: EQ-5D 
and SF-6D (the latter derived from the SF-12 version 2 [9]). 
The EQ-5D has five dimensions with three severity levels, 
describing 243 health states [7], and a preference-based 
score ranging from 1 (best state) to -0.594 (i.e., 0 is equiva-
lent to a state of dead, and negative values are equivalent to 
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states valued as worse than dead) [8]. The SF-6D has six 
dimensions, with between four and six response levels, and 
preference-based score ranging from 1 (perfect health) to 
0.345 (worst state) [9].
2.2.2  Clinician‑Reported Measures
Clinician-reported measures included the PANSS; a 30-item, 
7-point schizophrenia syndrome scale from 1 (absent) to 
7 (extreme), which can be summed across or within three 
subscales: positive (seven items, score range 7–49); negative 
(seven items, score range 7–49); general psychopathology 
(16 items, score range 16–112); total score range 30–210 
[15]. The CGI-SCH was used to assess the severity of schiz-
ophrenia (five items) in positive, negative, cognition, depres-
sion, and overall symptoms [16]. All items are rated on a 
7-point scale, from 1 (normal/not ill) to 7 (among the most 
severely ill), with no overall score produced [16]. Negative 
symptoms associated with schizophrenia were assessed 
using the Negative Symptoms Assessment (NSA-4) [22] 
7-point global rating scale (negative symptoms over the last 
7 days). Finally, clinicians also completed the Health of the 
Nation Outcome Scales for Payment by Results (HoNOS-
PbR) designed by UK psychiatrists for use in routine clinical 
practice as a record of a patient’s progress across 12 items 
[23]: behavior (three items), function (two items), symptoms 
(three items), and social (four items); a total score can be 
derived via summation of the 12 items.
2.3  Exploratory Validity Analysis
This analysis is considered exploratory as no a priori 
assumptions were made about the relationship between the 
clinician- and patient-reported measures; rather, the relation-
ships identified will inform a discussion about the level of 
association between these measures, their uses in measuring 
the burden of schizophrenia, and areas for future research 
in a patient population with schizophrenia. Therefore, to 
explore the relationship of the patient-reported HRQoL 
measures in patients with schizophrenia versus clinician-
reported measures, floor and ceiling effects and construct 
validity were explored.
Floor and ceiling effects are important to assess as, within 
cross-sectional studies, they can be used as a proxy of sensi-
tivity in relation to how well a measure can detect changes 
in HRQoL. For example, if a large proportion of the sam-
ple is at the floor (a score representing the highest level of 
symptoms or poor functioning) or ceiling (a score represent-
ing no problems), this impairs the ability (sensitivity) of 
the measure to pick up decreases or increases in HRQoL, 
respectively. The presence of floor and ceiling effects and 
data distribution (histograms are presented in Appendix S1 
in the Electronic Supplementary Material [ESM]) were used 
to select the appropriate statistical tests to assess construct 
validity; that is, if the data were non-normally distributed 
and affected by floor and ceiling effects, nonparametric tests 
were preferred to parametric tests.
Construct validity refers to the extent to which an instru-
ment measures what it is intended to measure (e.g., HRQoL) 
compared with other indicators. To do this, a “gold stand-
ard” is required against which to assess the measures of 
interest. However, because no gold standard measure cover-
ing the full complex nature of “mental health” or schizophre-
nia exists, we used a range of clinician-reported measures 
as indicators. Two related types of construct validity were 
undertaken: convergent and known-group.
Convergent validity was used to assess the relationship 
strength between measures. This can be done using corre-
lation analysis and locally weighted scatterplot smoothing 
(LOWESS) techniques. Here, correlation analysis indicates 
the degree to which the instruments measure related factors 
at the overall, dimension, or item level. Correlation associa-
tions were considered weak if scores were ≤ 0.3, moderate 
if 0.3 < 0.5, and strong if ≥ 0.5 [24]; statistical significance 
was defined at the 5% threshold level. Spearman’s rank cor-
relation coefficient was used as a nonparametric test based 
on the score distribution across the measures (see Sects. 3.1 
and 3.2). LOWESS is a form of nonparametric regression 
that plots a line of central tendency between two variables on 
a scatterplot, thereby visualizing the relationship across the 
possible score ranges. LOWESS captures general patterns 
in the relationship between two measures without making 
assumptions about their actual relationship.
Known-group validity assesses the extent to which 
scores on an instrument differ across groups where they are 
expected to differ (e.g., clinical severity indicators). This 
can be measured by calculating effect sizes (calculated as 
the difference in mean scores between two adjacent sever-
ity subgroups divided by the standard deviation of scores 
for the milder of the two subgroups) between groups that 
provide a standard indicator of the size difference. Cohen’s 
d was used to calculate standardized effect sizes and the 
p value calculated from the F statistic. Effect sizes ≤ 0.5 
were considered small, 0.5 < 0.8 moderate, and ≥ 0.8 large 
[24]; statistical significance was defined at the 5% threshold 
level. For this assessment, a focused literature search was 
performed to identify already established clinically mean-
ingful severity cut-off points for the clinical measures. If 
cut-off points could not be identified, ad-hoc cut-offs were 
established based on the score format and distribution of 
the measure to inform this exploratory analysis; that is, the 
authors assessed the score format (e.g., if based on a con-
tinuous or categorical scale) then identified what proportion 
of patients were distributed across this score range, whereby 
an ad-hoc cut-off was based on establishing an equal pro-
portion of people between two or more groups such that 
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enough variation existed in each group that a meaningful 
known-group effect size could be identified if one existed. 
Ad-hoc cut-offs were used for the PANSS, CGI-SCH, and 
the NSA-4, whereas established cut-offs from the literature 
were used for the HoNOS-PbR [25]. It should be noted that 
established cut-offs for the PANSS were identified from the 
literature, but were based on a percentage change in scores 
over time (i.e., requiring data to be collected from at least 
two time points) and therefore could not be used for this 
cross-sectional study [26]. These cut-offs are reported in 
the results, and the implications of using ad-hoc cut-offs are 
included in the discussion.
We assumed clinician-reported measures represent 
the “true state” of patients in the absence of any inherent 
“gold standard” for this assessment. Therefore, a moder-
ate to strong/large correlation and known-group effect size 
between the clinician-reported and patient-reported meas-
ures suggests construct validity of the patient-reported meas-
ures. Convergent validity between different patient-reported 
measures may be used as an estimate of the coherence and 
consistency of patient report and thus the potential impact 
of invalid or random responses (e.g., due to schizophrenia-
related cognitive impairment [14]) on the reliability of the 
overall construct validity assessment of the measures in this 
population.
Across the head-to-head assessments, the frequency of 
producing the strongest absolute correlation strength (ACS), 
largest absolute effect size (AES), and statistically signifi-
cant results will be used to determine the best overall con-
struct validity between patient-reported measures. Evidence 
to suggest the existence of floor-and-ceiling effects, or inva-
lid or random responses (i.e. evidence of poor convergent 
validity between patient-reported measures), will be used 
to inform the suggested reliability of these construct valid-
ity results.
3  Results
Overall, 304 patients consented to the study; however, as the 
WEMWBS was included in the protocol later in the process, 
it was included for only 297 patients. A summary of patient 
and condition characteristics is provided in Table 1; measure 
scores and completion rates are presented in Tables 2 and 3. 
Based on the clinician-reported scores, these patients were 
defined as having a “mild” NSA-4 global negative rating 
score and “mildly” severe CGI-SCH symptoms.
3.1  Floor and Ceiling Effects
Floor and ceiling effect statistics are presented in Tables 4 
and 5. In general, all of the clinical measures had evidence 
of ceiling effects; this was less apparent with the PANSS and 
HoNOS-PbR total, but not the subscale scores. The EQ-5D 
had issues with ceiling effects; this was less apparent for 
other patient-reported measures.
3.2  Convergent Validity
All correlation coefficients are presented in Tables 6 and 
7. In summary, amongst the patient-reported measures, the 
SF-6D most frequently (six times) exhibited the strongest 
correlations against the clinician-reported measure scores, 
with the SQLS Psychosocial, WEMWBS, and EQ-5D exhib-
iting the strongest strength correlation three times each. The 
SQLS Symptoms subscale did not strongly correlate with 
any of the clinician-reported measures. 
Between patient-reported measures, all correlations were 
of moderate to strong strength and statistically significant 
(the exception being any correlations with the SQLS Moti-
vation subscale, which were of weak strength and had one 
Table 1  Summary of patient and condition characteristics (N = 304)
Data are presented as n (%) or mean (range) unless otherwise indi-
cated
NICE National Institute for Health and Care Excellence
a Characteristics about the patient’s condition were only collected for 
a subgroup of the study cohort (i.e., 166 people; 55% of the study 
cohort)
b The mean time since diagnosis for this subgroup was 12.1  years, 
but the mean time in treatment since diagnosis was 12.8 years–based 
on the mean times, treatment for this patient group may have started 
before diagnosis. NICE’s recommendation to begin assessment 
“without delay” may have resulted in this patient group receiving 
treatment before a full diagnosis was confirmed [33], which possibly 
explains this difference in time between diagnosis and treatment
Variable Statistic
Age: all patients, n (range) 42 (20–70)
Age: groups
 20–29 39 (12.8)
 30–39 83 (27.3)
 40–49 96 (31.6)
 50–59 69 (22.7)
 60–70 17 (5.6)
Male sex 237 (78)
Ethnicity
 White 246 (80.9)
 Mixed 6 (2.0)
 Asian or Asian British 22 (7.3)
 Black or Black British 30 (9.9)
Characteristics of patient’s condition for N = 166a
 Time since diagnosis of schizophrenia (years)b 12.1 (0–46)
 Time in treatment since diagnosis (years)b 12.8 (0–46)
 Duration of negative symptoms (years) 11.2 (0–46)
 Duration of positive symptoms (years) 12.4 (0–46)
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Table 2  Summary and 
descriptive statistics of patient 
reported-outcomes measure 
scores
EQ-5D EuroQoL Five-Dimension, SD standard deviation, SF-6D Short-Form Six-Dimension, SQLS Schiz-
ophrenia Quality-of-Life Scale, WEMWBS Warwick-Edinburgh Mental Wellbeing Scale
a Patient- and clinician-reported measures could have been completed for N = 304, apart from for the WEM-
WBS measure, which was for N = 297
Short name No. completed, 
N (%)a
Mean Median SD Minimum Maximum
EQ-5D tariff score 304 (100) 0.69 0.74 0.27 − 0.18 1
SF-6D tariff score 302 (99.3) 0.67 0.66 0.12 0.35 1
SQLS Psychosocial 303 (99.7) 43.09 43.33 15.73 8 85
SQLS Motivation 304 (100) 55.73 53.57 10.58 25 96
SQLS Symptoms 303 (99.7) 34.02 34.38 15.08 3 78
WEMWBS 251 (84.5) 43.78 44 9.58 14 67
Table 3  Summary and 
descriptive statistics of 
clinician-reported outcomes 
measure scores
CGI-SCH Clinical Global Impression-Schizophrenia Change, HoNOS-PbR Health of the Nation Outcome 
Scales for Payment by Results, NSA-4 Negative Symptoms Assessment, PANSS Positive and Negative 
Symptom Scale, SD standard deviation
a Patient- and clinician-reported measures could have been completed for N = 304, apart from for the WEM-
WBS measure which was for N = 297
Short name No. completed, 
N (%)a
Mean Median SD Minimum Maximum
PANSS total 303 (99.7) 65.43 66 17.16 31 122
PANSS Positive 303 (99.7) 15.69 16 5.24 7 36
PANSS Negative 303 (99.7) 17.19 16 6.02 7 35
PANSS Psychopathology 303 (99.7) 32.54 33 8.86 16 66
CGI-SCH Positive 303 (99.7) 2.97 3 1.18 1 6
CGI-SCH Negative 303 (99.7) 2.70 3 1.12 1 6
CGI-SCH Depressive 303 (99.7) 2.40 2 1.12 1 6
CGI-SCH Cognitive 303 (99.7) 2.46 2 1.06 1 5
CGI-SCH Overall 303 (99.7) 3.15 3 1.03 1 6
NSA-4 rating 303 (99.7) 3.01 3 1.29 1 6
HoNOS-PbR total 274 (90.1) 9.38 9 4.72 0 28
HoNOS-PbR Behavior 297 (97.7) 0.91 1 1.14 0 5
HoNOS-PbR Functional 301 (99.0) 1.81 2 1.31 0 6
HoNOS-PbR Symptoms 298 (98.0) 3.52 3.5 2.08 0 10
HoNOS-PbR Social 284 (93.4) 3.01 3 2.21 0 12
Table 4  Floor and ceiling effect 
assessment for patient-reported 
outcomes measures
EQ-5D EuroQoL Five-Dimension, SF-6D Short-Form Six-Dimension, SQLS Schizophrenia Quality-of-
Life Scale, WEMWBS Warwick-Edinburgh Mental Wellbeing Scale
a Patient- and clinician-reported measures could have been completed for N = 304, apart from for the WEM-
WBS measure which was for N = 297
Short name No. completed, 
N (%)a
Floor score/
worst state
Ceiling score/
best state
N (%) floor/
worst state
N (%) ceil-
ing/best 
state
EQ-5D tariff score 304 (100) − 0.594 1 0 (0) 49 (16.1)
SF-6D tariff score 302 (99.3) 0.345 1 0 (0) 4 (1.3)
SQLS Psychosocial 303 (99.7) 100 0 0 (0) 0 (0)
SQLS Motivation 304 (100) 100 0 0 (0) 0 (0)
SQLS Symptoms 303 (99.7) 100 0 0 (0) 0 (0)
WEMWBS 251 (84.5) 14 70 1 (0.4) 0 (0)
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Table 5  Floor and ceiling 
effect assessment for clinician-
reported outcome measure
CGI-SCH Clinical Global Impression-Schizophrenia Change, HoNOS-PbR Health of the Nation Outcome 
Scales for Payment by Results, NSA-4 Negative Symptoms Assessment, PANSS Positive and Negative 
Symptom Scale, SD standard deviation
Short name No. completed, 
N (%)
Floor score/
worst state
Ceiling score/
best state
N (%) Floor/
worst state
N (%) Ceil-
ing/best state
PANSS total 303 (99.7) 210 30 0 (0) 0 (0)
PANSS Positive 303 (99.7) 49 7 0 (0) 14 (4.6)
PANSS Negative 303 (99.7) 49 7 0 (0) 8 (2.6)
PANSS Psychopathol-
ogy
303 (99.7) 112 16 0 (0) 2 (0.7)
CGI-SCH Positive 303 (99.7) 7 1 0 (0) 37 (12.2)
CGI-SCH Negative 303 (99.7) 7 1 0 (0) 47 (15.5)
CGI-SCH Depressive 303 (99.7) 7 1 0 (0) 75 (24.8)
CGI-SCH Cognitive 303 (99.7) 7 1 0 (0) 61 (20.1)
CGI-SCH Overall 303 (99.7) 7 1 0 (0) 18 (5.8)
NSA-4 rating 303 (99.7) 7 1 0 (0) 30 (9.9)
HoNOS-PbR total 274 (90.1) 48 0 0 (0) 2 (0.7)
HoNOS-PbR Behavior 297 (97.7) 12 0 0 (0) 138 (46.5)
HoNOS-PbR Functional 301 (99.0) 8 0 0 (0) 55 (18.3)
HoNOS-PbR Symptoms 298 (98.0) 12 0 0 (0) 25 (8.4)
HoNOS-PbR Social 284 (93.4) 16 0 0 (0) 34 (12.0)
Table 6  Correlation coefficient matrix between patient and clinician-reported outcomes measures
Cohen’s cut-offs: <  0.3 = weak; 0.3  <  0.5 = moderate; ≥  0.5 = strong; bold formatting indicates moderate or strong, and italics indicates the 
strongest strength correlation across patient-reported or caregiver-reported measure
CGI-SCH Clinical Global Impression-Schizophrenia Change, EQ-5D EuroQoL Five-Dimension, HoNOS-PbR Health of the Nation Outcome 
Scales for Payment by Results, NSA-4 Negative Symptoms Assessment, PANSS Positive and Negative Symptom Scale, SF-6D Short-Form Six-
Dimension, SQLS Schizophrenia Quality-of-Life Scale, WEMWBS Warwick-Edinburgh Mental Wellbeing Scale
*p < 0.05
Measure reporter Measure Patient-reported measures
SQLS 
Psycho-
social
SQLS Motivation SQLS Symptoms WEMWBS EQ-5D tariff SF-6D tariff
Clinician-reported meas-
ures
PANSS total 0.214* 0.093 0.133* − 0.238* − 0.229* − 0.274*
PANSS Positive 0.225* 0.128* 0.131* − 0.224* − 0.212* − 0.277*
PANSS Negative 0.017 − 0.037 − 0.014 − 0.158* − 0.034 − 0.084
PANSS Psychopa-
thology
0.243* 0.104 0.174* − 0.220* − 0.264* − 0.285*
CGI-SCH Positive 0.265* 0.072 0.210* − 0.270* − 0.297* − 0.327*
CGI-SCH Negative 0.047 − 0.047 0.015 − 0.172* − 0.142* − 0.121*
CGI-SCH Depressive 0.413* 0.122* 0.170* − 0.302* − 0.298* − 0.368*
CGI-SCH Cognitive 0.020 − 0.027 0.051 − 0.033 − 0.179* − 0.110
CGI-SCH Overall 0.300* 0.047 0.231* − 0.297* − 0.312* − 0.355*
NSA-4 rating 0.191* 0.083 0.095 − 0.272* − 0.175* − 0.282*
HoNOS-PbR total 0.426* 0.127* 0.323* − 0.374* − 0.432* − 0.421*
HoNOS-PbR Behav-
ior
0.210* 0.084 0.143* − 0.197* − 0.199* − 0.200*
HoNOS-PbR Func-
tional
0.092 − 0.009 0.256* − 0.139* − 0.327* − 0.256*
HoNOS-PbR Symp-
toms
0.529* 0.157* 0.316* − 0.396* − 0.414* − 0.436*
HoNOS-PbR Social 0.285* 0.053 0.195* − 0.303* − 0.245* − 0.255*
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statistically non-significant correlation). This provides some 
evidence of coherent and consistent self-reporting of out-
comes across these measures. The scatter plots and LOW-
ESS lines provided further support of convergent validity 
between clinician-reported and patient-reported measures, 
the results and figures for which are described and presented 
in Appendix S2 in the ESM.
3.3  Known‑Group Validity
All effect sizes are presented in Tables 8 and 9. Although 
the overall majority of effect sizes were small, the SQLS 
Psychosocial, WEMBS, EQ-5D, and SF-6D each indicated 
some medium to large effect sizes across the clinician-
reported measures (but not with the PANSS); all medium to 
large effect sizes were statistically significant. The WEM-
WBS indicated a medium effect size between the NSA-4 
“mild” and “moderate to severe” cut-offs and was the only 
patient-reported measure to indicate anything but a small 
effect size between the NSA-4 groups. Across clinician-
reported measures, the WEMWBS, EQ-5D, and SF-6D 
more often indicated a larger effect size than the SQLS Psy-
chosocial, Motivation, or Symptoms subscales. 
4  Discussion
A total of 304 patients with persistent symptoms of schizo-
phrenia were recruited to a UK-based cross-sectional sur-
vey. These exploratory results suggest that, when patient-
reported measures (EQ-5D, SF-6D, WEMWBS, SQLS 
subscales of Psychosocial, Motivation, and Symptoms) were 
assessed against clinician-reported measures (PANSS, CGI-
SCH, NSA-4, HoNOS-PbR), the patient-reported EQ-5D, 
SF-6D, WEMWBS, and SQLS Psychosocial subscale had 
moderate construct validity in patients with schizophrenia. 
There was less support for the construct validity of the SQLS 
Symptoms subscale and nearly no support for the SQLS 
Motivation subscale. There was also evidence of consistent 
reporting of outcomes between the patient-reported meas-
ures, which suggests that those with schizophrenia in this 
patient sample could report their HRQoL consistently across 
measures.
4.1  Floor and Ceiling Effects
The EQ-5D had some issues with ceiling effects, which is a 
common finding across different conditions [27]; these ceil-
ing effects were less apparent for the other patient-reported 
measures. The high ceiling effect suggests that, for a propor-
tion of patients, the dimensions of EQ-5D are not sensitive 
to their schizophrenia-specific ill health. The five-level EQ-
5D-5L was developed in an attempt to improve sensitivity 
to changes in health and address the ceiling effect issues 
associated with the EQ-5D [28].
4.2  Construct Validity
Our results suggest that only the condition-specific SQLS 
Psychosocial subscale in some cases indicated better con-
struct validity than the generic measures, depending on the 
clinician-reported measure used for analysis; however, the 
SQLS Motivation and Symptom subscales always indicated 
weak construct validity, and the SF-6D more often indicated 
the better construct validity than any other patient-reported 
measure. For the EQ-5D and SF-6D, these results were 
similar to previous studies in this patient population [29]. 
The identified statistically significant correlations between 
patient-reported measures suggested reasonably consist-
ent reporting of HRQoL across self-reported measures, 
Table 7  Correlation coefficient matrix between patient-reported outcome measures
Cohen’s cutoffs: <  0.3 = weak, 0.3  <  0.5 = moderate, ≥  0.5 = strong; bold formatting indicates moderate or strong, and italics indicates the 
strongest strength correlation across patient-reported or caregiver-reported measure
EQ-5D EuroQoL Five-Dimension, SF-6D Short-Form Six-Dimension, SQLS Schizophrenia Quality-of-Life Scale, WEMWBS Warwick-Edin-
burgh Mental Wellbeing Scale
*p < 0.05
Measure reporter Measures Patient-reported measures
SQLS Psychosocial SQLS Motivation SQLS Symptoms WEMWBS EQ-5D tariff SF-6D 
tariff
Patient-reported 
measures
SQLS Psychosocial 1 0.268* 0.574* − 0.631* − 0.480* − 0.670*
SQLS Motivation 0.268* 1 0.082 − 0.148* − 0.203* − 0.252*
SQLS Symptoms 0.574* 0.082 1 − 0.386* 0.458* − 0.450*
WEMWBS − 0.631* − 0.148* − 0.386* 1 0.406* 0.542*
EQ-5D tariff − 0.480* − 0.203* 0.458* 0.406* 1 0.637*
SF-6D tariff − 0.670* − 0.252* − 0.450* 0.542* 0.637* 1
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providing some reliability to the exploratory construct valid-
ity assessment.
A consistent result across these patient-reported meas-
ures was a lack of construct validity with schizophrenia-
related negative symptoms (i.e., PANSS and CGI negative 
subscales), suggesting these measures may not be appropri-
ate for assessing negative aspects of schizophrenia, a result 
echoing those of a previous study [17]. The WEMWBS was 
relatively more useful in assessing negative symptoms (i.e., 
CGI-SCH negative subscale and NSA-4), albeit this was not 
unexpected given it focuses on psychological wellbeing.
4.3  Implications for Clinical Research and Economic 
Evaluations
Although this study provides some exploratory evidence to 
suggest moderate construct validity for the generic meas-
ures used as part of the analysis, there is limited evidence 
of strong construct validity and so a new measure focused 
around mental health is still desirable to improve on the 
validity performance of these current measures. In particu-
lar, patient-reported measures compared with clinician-
reported measures appear less able to capture the impact of 
negative symptoms.
Despite the use of a schizophrenia-specific measure 
(i.e., SQLS) to capture condition-specific aspects of schizo-
phrenia, the construct validity results suggested the SQLS 
provided little benefit over the generic HRQoL measures 
included in the analysis (particularly the SF-6D). This would 
therefore suggest a need to develop patient-reported meas-
ures that better elucidate and quantify aspects of schizophre-
nia, such as negative symptoms [29]. However, regarding 
this previous point, the assumption that patient-reported 
measures are valid only insofar as they approximate to cli-
nician-reported measures is a convenient assumption often 
used for statistical validation exercises but is flawed and 
highlights a rather patriarchal approach. Clinician- and self-
reported measures are two different perspectives on an indi-
vidual’s experience and can offer complementary (i.e., ask-
ing the clinician will produce different but complementary 
information to that produced by asking the patient) rather 
than substitutive or equivalent information (i.e., asking the 
clinician should produce similar information to that pro-
duced by asking the patient). It would be unusual for patient-
reported and clinical-reported measure scores to show 
perfect agreement. This difference between patient- and 
clinician-reported outcomes has been attributed to aspects 
such as schizophrenia-related cognitive impairment, which 
impairs the patient’s ability to comprehend and report on 
their own condition [14]. However, individual experiences 
are not rendered more accurate through some ill-defined her-
meneutic process of interpretation, and the subjective–objec-
tive discrepancy in measurement may not be considered as 
evidence of a failure of the subjective measure. The practical 
utility of the SQLS Motivation and Symptoms subscales, 
given the poor construct validity results, should be inter-
preted with this in mind. Classifying and quantifying the 
complexities of an individual’s experience is a significant 
challenge, especially with a poorly understood, ill-defined 
mental health disorder such as schizophrenia. This is further 
compounded by myriad internal and external factors that 
influence assessment, attribution, and communication by 
the patient, not least of which is the person’s “mood” at the 
time of responding to subjective measurement tools, which 
should be interpreted in this light [18].
4.4  Limitations
Patients in the sample were mainly those with mild symp-
toms, which negates the generalizability of these results to 
outcomes measurement in a more severe population. The 
lack of clinically meaningful cut-offs identified in the lit-
erature meant we relied on ad-hoc cut-offs to assess known-
group validity. Therefore, these results may not be gener-
alisable to other similar studies, and the cut-offs may have 
had an effect on the interpretation of known-group validity. 
However, for this exploratory analysis, the use of ad-hoc 
cut-offs provided informative results about the ability of the 
patient-reported measures to detect statistically significant 
effect sizes between groups, which can be compared with the 
results of future studies when and if clinically meaningful 
cut-offs are established for the PANSS, CGI-SCH, and NSA-
4. Ceiling effects within particular measures (e.g., EQ-5D) 
may have affected correlation analysis, but the known-group 
validity was used to confirm results. The data were also 
cross-sectional, so change over time could not be assessed, 
which is an important aspect to assess in the context of eco-
nomic evaluation.
As stated in the introduction, evidence suggests that, in 
people with schizophrenia, self-report should be interpreted 
with caution, as condition-related aspects such as cognitive 
impairment may impair reliability [14]. This is an inherent 
concern when using self-reported data for outcomes assess-
ment in patients with mental health conditions that could 
impair their ability to provide reliable responses; however, 
we explored the convergent validity between the different 
patient-reported measures as an estimate of the coherence 
and consistency of patient self-report and thus the potential 
impact of invalid or random responses (e.g., due to schizo-
phrenia-related cognitive impairment [14]) on the reliability 
of the overall construct validity assessment of the measures 
in this population. This approach offered a practical solution 
to assessing the consistency of reporting between similar 
patient-reported measures when it was not possible to use 
other practical methods of assessing reliability in reporting 
within measures, such as assessing test–retest reliability, 
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which assesses intra-observer reliability within measures 
by asking the person to complete the same measure twice at 
different (but chronologically close together) time periods 
[19]. Our analysis suggested that people in our study cohort 
had reasonably consistent reporting of outcomes between 
patient-reported measures, as represented by the moderate 
to strong correlation strength and statistically significant 
results; however, as we could not specifically control for 
cognitive impairment (e.g., using regression analysis con-
trolling for a measure of cognitive impairment, such as the 
Mini Mental State Examination [30]), some aspects of cog-
nitive impairment could have affected our overall assess-
ment, which should be noted when interpreting our explora-
tory results.
Because of the large number of outcome measures col-
lected, multiple statistical tests were performed, which can 
increase the likelihood of erroneous inferences. Statistical 
methods exist to control for issues associated with multi-
ple testing (e.g., the Bonferroni correction [31]); however, 
because of the stricter statistical significance threshold asso-
ciated with these methods, a large sample size is required 
to identify a statistically significant result. Trials tend not to 
be powered for multiple testing (as most trials are powered 
based on a single primary outcome), so, for this explora-
tory analysis using data from a cross-sectional survey study, 
300 people were considered an adequate sample size within 
which corrections for multiple testing were not accounted, 
which is a limitation. Therefore, future studies may want 
to recruit larger sample sizes and apply statistical methods 
to control for multiple tests to confirm or refute the results 
identified within the current study.
4.5  Considerations for Future Research
Although this study provides exploratory evidence to sug-
gest moderate construct validity for the generic measures 
used as part of this analysis, there is limited evidence of 
strong convergent validity, so a new measure focused around 
mental health is still desirable to improve on the validity 
performance of these current measures. Related to this point, 
preference-based measures that can be used for the purpose 
of clinical assessment and economic evaluation in the field 
of mental health research are also lacking. Two new meas-
ures (which were unavailable at the time of the study that 
produced the data for this analysis) have undergone initial 
validation and have been developed to assess QoL in peo-
ple with different mental health conditions [32]: Recover-
ing Quality of Life (ReQoL) measure with 10 (ReQoL-10; 
there are plans to make this version preference-based) or 
20 (ReQoL-20) items. The intention is that these measures 
will “plug a gap” in capturing aspects of QoL important 
to people with mental health conditions (including those 
with schizophrenia) for clinical assessment and economic 
evaluations. Given that the results from this and previous 
studies have provided mixed evidence for the appropriate-
ness of using the EQ-5D and SF-6D for economic evalu-
ations [11–13, 29], using an alternative preference-based 
measure in patients with schizophrenia (such as the ReQoL-
10) should be explored as part of future research. Under-
standing how the ReQoL measures compare with existing 
non-preference-based measures in this patient population 
(e.g., the SQLS and WEMWBS) will inform the measure’s 
use for clinical outcome assessment.
5  Conclusion
The exploratory results from this study suggest that the 
patient-reported measures showed moderate construct valid-
ity when assessed against clinician-reported measures for 
some aspects of schizophrenia severity but showed weak 
construct validity for the negative symptoms of the condi-
tion. In particular, the SF-6D had the best overall construct 
validity but showed a weak relationship with clinician-
rated measures for negative symptoms. Compared with the 
EQ-5D, the SF-6D may better capture HRQoL aspects of 
schizophrenia for the purpose of economic evaluation. How-
ever, a new measure to assess the burden of schizophrenia is 
still desirable to improve on the psychometric properties of 
existing measures for this patient population. There was evi-
dence of consistent reporting of outcomes between patient-
reported measures, which provides exploratory evidence that 
patients with schizophrenia can self-report their HRQoL. 
There is a suggestion that the SQLS can be self-reported 
to capture complementary information relative to clinician-
reported measures, which is desirable when quantifying the 
wider burden of schizophrenia.
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